Omalizumab Retreatment and Step-Up in Patients with Chronic Spontaneous Urticaria: OPTIMA Trial
Publication date: Available online 6 April 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Gordon Sussman, Jacques Hébert, Wayne Gulliver, Charles Lynde, William H. Yang, Kim Papp, Melinda Gooderham, Olivier Chambenoit, Sam Khalil, Frederica DeTakacsy, Antonio Vieira, Lenka Rihakova
ConclusionAlthough the clinical benefit of omalizumab in asthma and chronic spontaneous urticaria (CSU) has been established in several clinical trials, there are very little data about its effect on severe VKC. In addition to few previously reported cases we can report the rapid effectiveness of omalizumab in VKC clinically and in terms of quality of life. Randomized trials are needed to include omalizumab in third-line treatment of VKC for prevention of visual impairment and further sequelae such as corneal damage.
AbstractChronic spontaneous urticaria (CSU) is defined as the spontaneous development of itchy hives and/or angioedema due to known or unknown causes that last for at least 6 weeks. At any given time, CSU is believed to affect 0.5–1% of the global population. Omalizumab (a recombinant, humanized anti-immunoglobulin-E antibody) is the only approved treatment for antihistamine refractory CSU. However, ~ 30% of patients remain symptomatic at licensed doses of omalizum ab 150 mg and 300 mg, even after a treatment period of over 6 months. In the recent years, there have been several studies on ...
Authors: Lee MS, Yoon J, Kim J, Shin YS, Park HS, Lee HY, Ye YM Abstract PURPOSE: A need for useful measures reflective of the socio-economic burden of chronic urticaria (CU) has arisen. To obtain utility estimates for CU, we investigated EuroQol-5-Dimension (EQ-5D) indices according to urticaria control status and urticaria severity. METHODS: In this prospective observational study, we administered patient-oriented questionnaires on EQ-5D and urticaria outcomes, including Urticaria Activity Score over 7 days (UAS7), Urticaria Control Test (UCT), and CU-specific quality of life (CU-QOL). EQ-5D utility index sco...
Authors: Song WJ, Choi M, Lee DH, Kwon JW, Kim GW, Kim MH, Kim MA, Kim MH, Kim BK, Kim S, Kim JS, Kim JE, Kim JY, Kim JH, Kim HJ, Kim HO, Kim HB, Roh JY, Park KH, Park KY, Park HK, Park H, Bae JM, Byun JY, Song DJ, Ahn YM, Lee SE, Lee YB, Lee JS, Lee JH, Lim KH, Ye YM, Chang YS, Jeon YH, Jeon J, Jue MS, Choi SH, Choi JH, Hur GY, Park YM, Lim DH, Youn SW Abstract Chronic spontaneous urticaria (CSU) is defined as the occurrence of spontaneous wheals, angioedema, or both for>6 weeks in the absence of specific causes. It is a common condition associated with substantial disease burden both for affected individuals a...
Authors: Lee JH PMID: 32400123 [PubMed]
ConclusionA multidisciplinary approach to the treatment of sinonasal symptoms using both escalation of medical therapy and surgical approaches may improve QOL of patients with suspected MCAS. Consensus criteria for MCAS, which includes elevation in tryptase over baseline during an episode, may exclude the full spectrum of individuals with MCAS from potentially beneficial treatment.
ConclusionThere is an urgent need for a simpler symptom- or system-based classification and scoring system to create an awareness for HSRs to BSs. A better understanding of the pathophysiology of HSRs and increased clinical experience in the treatment of side effects will provide timely control of unexpected reactions. As a result, im munotherapy with BSs will become safer in the future.
Authors: Asero R PMID: 32378398 [PubMed - as supplied by publisher]
Authors: Khan S, Sholtysek S PMID: 32378397 [PubMed - as supplied by publisher]
Conclusions.The AU etiology identified by history in the ED may be a significant predictor of persistence after a first attack of AU. PMID: 32372590 [PubMed - as supplied by publisher]